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Abstract 
Purpose: To evaluate the therapeutic effect of Epimedium brevicornum Maxim. extract (EBME) on 
ovariectomy-induced osteoporosis in rats. 
Methods: The rats were divided into six experimental groups, viz, control (group 1) and five 
ovariectomy-induced (OVX) groups. The OVX groups include OVX-inducing agent only group (group 2), 
OVX with 17ß-estradiol (E2, 25 µg/kg/day, group 3), OVX with 60 mg EBME/kg body weight/day (group 
4), OVX with 120 mg EBME/kg body weight/day (group 5) and OVX with 240 mg EBME/kg body 
weight/day (group 6). The treatment started for the OVX groups with a single weekly dose of OVX 
inducing agent for 4 weeks, followed by oral daily dose of E2 (group 3) or EBME (groups 4, 5 and 6) for 
another 16 weeks. Bone mineral density (BMD) of the 4th lumber vertebrae (4LV) and right femur of 
each rat was estimated. BMD determination was preceded by the measurement of the length of the 
femur and identification of diaphysis (center). Trabecular microarchitecture was assessed via three 
representative 4LV. The other parameters measured in this study were serum alkaline phosphatase 
(ALP), urinary calcium (U-Ca), urinary phosphorus (U-P), urinary creatinine (U-SCr) and osteocalcin 
(OC) levels. 
Result: The results showed that the BMD decrease induced by OVX in 4LV and femur was significantly 
mitigated by high dose of EBME. EBME also protected the trabecular microarchitecture against OVX-
associated deterioration, evidenced by decreased bone turnover marker levels in 4LV at high EBME 
dose. Trabecular number (Tb-N, 3.7 ± 0.2), trabecular thickness (Tb-Th, 0.082 ± 0.011), and trabecular 
spacing (Tb-Sp, 0.17 ± 0.01) of the highest dose EBME-treated OVX rats ’4LV were significantly (p < 
0.05) different from the corresponding values of EBME-free OVX rats.  
Conclusion: The results reveal that administration of high doses of EBME lasting for 16 weeks not only 
protected against OVX-induced osteoporosis in rats but was also without the risk of endometrial 
hyperplasia. Thus, the extract may be a better alternative to other agents in current use for the 
treatment of postmenopausal osteoporosis in elderly women. However, its efficacy and safety require 
further investigations.  
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Osteoporosis is a systemic skeletal disease 
characterized by decreased bone mass and 
deteriorated bone tissue. The disease causes 
bone fragility with increased susceptibility to 
fractures [1]. Based on the data from World 
Health Organization (WHO), millions of people 
are now suffering from osteoporosis throughout 
Europe, the USA, and China [2]. The morbidity 
rises dramatically with increasing life span. 
Accordingly, the risk of osteoporotic fractures 
and the associated costs correlates positively 
with advancing age. Hip fracture is among the 
major causes of death of the elderly [3].  
 
Hormone deficiency is known to impair proper 
development of metaphyseal cancellous bone 
strength as well as reduction in bone mineral 
density (BMD) in humans and animals. Presently 
the hormone whose deficiency is widely believed 
to be linked to osteoporosis in post-menopausal 
women is estrogen [4]. Osteoporosis is twice as 
common in women as in men, and approximately 
one in three women over 50 years old 
experience an osteoporotic fracture [5]. 
 
The most common therapy for postmenopausal 
osteoporosis is hormone replacement therapy 
(HRT) [6]. Nonetheless, HRT is a health 
management approach fraught with risk, the 
major one is the induction of cancer of the 
reproductive tissues [7]. Besides HRT, there are 
other drugs currently used for the treatment of 
osteoporosis which are neither readily available 
to, nor affordable by a large proportion of the 
world population in developing countries. Again, 
the drugs have side effects, such as 
gastrointestinal reactions, cancer induction, 
osteonecrosis of the jaw, and reduced skeletal 
strength. Therefore, the search for alternative 
therapeutic agents capable of prompting 
osteogenesis and/or impeding bone resorption 
but devoid of untoward side effects has 
continued to hold the attention of research 
scientists [8,9]. 
 
It is well known that Epimedium brevicornum 
Maxim. displays kidney-toning and anti-
osteoporosis effects, and is widely used herb in 
China for the treatment of nephrasthenia 
syndrome [10], osteoporosis, [11] and bone 
fracture [12].  
 
In this study, an in-depth investigation of 
Epimedium brevicornum Maxim. extract (EBME) 
as a possible anti-osteoporosis agent in 
ovariectomy (OVX) - induced osteoporosis in rats 




Preparation of Epimedium brevicornum 
Maxim. extract 
 
The herb, Epimedium brevicornum Maxim., was 
collected in Nanning City, Guangxi Province, 
China, in October 2015. It was identified by 
Professor Lin He, and a voucher specimen (no. 
EBME 201509015) was deposited at the 
herbarium of College of Pharmacy, Wenzhou 
Medical University. One batch of the herbal 
sample of Epimedium brevicornum Maxim. was 
dried in an oven, and thereafter, immersed in 
water at 60 oC for 1 h to obtain the initial extract. 
This extraction process was repeated thrice, and 
the pooled extracts were freeze-dried. One gram 
of the extract powder was obtained from 
approximately 1.6 g herbal sample, giving a yield 
of 62.5 %. 
 
Treatment of animals 
 
Healthy, three-month-old female Sprague-
Dawley rats (weight 200 ± 20 g) were supplied by 
the Experimental Animal Center of Zhejiang 
Province (Certificate no. SYXK2002-0005). They 
had free access to feed and water, and were 
allowed to acclimatize to the laboratory 
conditions for at least one week, before the study 
commenced. The animal studies were approved 
by the Animal Care and Use Committee of 
Wenzhou Medical University (approval ref no. 
20100407). The animal studies were carried out 
according to Directive 2010/63/EU guidelines for 
the use of animals for scientific purposes [13].  
 
The sixty rats used for this study were divided 
into six experimental groups of ten rats each. 
They were group 1, the control group, and the 
ovariectomy (OVX) groups (groups 2-6). Group 2 
rats received only the OVX agent. Group 3 rats 
were the OVX category given 17ß-estradiol (E2, 
25 mg/kg/day). Group 4 rats were the OVX 
group, given 60 mg EBME/kg/day. Groups 5 and 
6 were also OVX rats, but were given 120 and 
240 mg EBME respectively /kg/day. The 
treatments started with single weekly dose of 
OVX agent for 4 weeks (all OVX rats), followed 
by oral daily dose of E2 (group 3 rats) or EBME 
(groups 4, 5 and 6) for another 16 weeks. 
 
Bone mineral density measurement 
 
Dual-energy X-ray absorptiometry scanning 
(DEXA, GE Healthcare, USA) for small animal 
measurements was employed for the estimation 
of the BMD of the 4th lumber vertebrae and right 
femurs. The results of the measurements were 
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presented as mineral contents (g)/surface areas 
(cm2).  
 
Three-point bending test 
 
The rats were sacrificed by cervical dislocation 
and thereafter the femur bones were carefully 
disarticulated and cleaned. Afterwards the length 





After each rat has been sacrificed by cervical 
dislocation, urine was obtained from it by 
stimulating the dorsal region, near the hind limbs. 
An automatic analyzer (Ciba-Corning 550, USA) 
was used for the measurement of the levels of 
serum alkaline phosphatase (ALP), urinary 
calcium (U-Ca), urinary phosphorus (U-P), and 
urinary creatinine (U-Cr) using diagnostic reagent 
kits. An osteocalcin (OC) ELISA kit (San 
Clemente, CA, USA) was used for the assay of 




The results are shown as mean ± SD. One-way 
ANOVA combined with Bonferroni’s multiple 
comparison test were used for data comparison 
while SPSS 16.0 software was used for statistical 
analysis. Criterion for statistical significant was 




BMD of 4th lumbar vertebra and femur 
 
The values of the BMDs of the 4th lumber 
vertebrae and femurs are presented in Table 1. 
These results show that the BMDs of the 4th 
lumber vertebrae and femurs were significantly 
(p < 0.05) reduced as a result of ovariectomy, 
when compared to the control group. However, 
EBME treatment caused significant (p < 0.05) 
increase in BMDs of the 4th lumber vertebrae and 
femurs of OVX-induced rats compared with OVX-
induced rats not treated with EBME. The 
increase was in a dose-dependent manner. 
 
Mechanical characteristics of femur 
 
The results of the mechanical characteristics of 
the femur bones are presented in Table 2. 
Compared with the control group, the tolerable 
maximum load and maximum stress limits 
decreased significantly (p < 0.05) in the estrogen 
deficient (ovariectomy) rats. However, the higher 
doses of EBME (80 or 160 mg/kg/day) caused 
significant (p < 0.05) increase in these 
parameters when compared to the EBME-free 
OVX rats. E2 also increased these biomechanical 
parameters, compared to those of the OVX 
group significantly (p < 0.05). The effect of H-
EBME on maximum load was similar to that of 
E2. 
 
        Table 1: Effect of EBME on BMD of 4th lumber vertebrae and femurs  
 
Group Dosage (mg/kg) BMD of vertebrae (g/cm2) 
BMD of 
femurs(g/cm2) 
Control - 0.25 ± 0.03* 0.23 ± 0.03* 
OVX - 0.14 ± 0.03 0.12 ± 0.03 
E2 0.025 0.20 ± 0.03 0.18 ± 0.03 
L-EBME+ 60 0.19 ± 0.04* 0.15 ± 0.02* 
M-EBME 120 0.21 ± 0.02* 0.18 ± 0.03* 
H-EBME 240 0.24 ± 0.01* 0.21 ± 0.02* 
*P < 0.05 and **p < 0.01 versus OVX group; +L / M / H-EBME: low / middle / high  
dose of EBME (n = 10 rats) 
 
        Table 2: Effect of EBME on femur mechanical properties (n = 10 rats) 
 
Group Dose (mg/kg) Maximum load (N) 
Maximum stress 
(MPa) 
Control - 131.5 ± 5.3* 203.5 ± 6.5* 
OVX - 94.7 ± 4.5 164.3 ± 5.6 
E2 0.025 123.6 ± 5.2* 184.7 ± 4.8* 
L-EBME+ 60 98.2 ± 4.9 153.6 ± 4.4 
M-EBME 120 108.2 ± 5.2* 169.3 ± 5.1* 
H-EBME 240 114.3 ± 5.1* 173.1 ± 5.0* 
       *P < 0.05 and **p < 0.01 versus OVX group; + L/M/H-EBME: low/middle/high dose of EBME 
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  Table 3: Effect of EBME on morphometric parameters in L4 vertebrae 
 
Group Dose (mg/kg) Tb-N (1/mm) Tb-Th (mm) Tb-Sp (mm) 
Control - 5.2 ± 0.3* 0.094 ± 0.014* 0.12 ± 0.01* 
OVX - 2.7 ± 0.4 0.061 ± 0.012 0.38 ± 0.02 
E2 0.025 4.3 ± 0.4* 0.085 ± 0.014* 0.16 ± 0.01* 
L-EBME+ 60 2.9 ± 0.3 0.069 ± 0.015 0.29 ± 0.03 
M-EBME 120 3.6 ± 0.3* 0.073 ± 0.012* 0.25 ± 0.02* 
H-EBME 240 3.7 ± 0.2* 0.082 ± 0.011* 0.17 ± 0.01* 
*P < 0.05 and **p < 0.01 versus OVX group. + L/M/H-EBME: low/middle/high dose of  
EBME (n = 10 rats) 
 
Table 4: Effect of EBME on biochemical parameters in the serum and urine 
 
Group Dose (mg/kg) U-Ca/Cr  U-P/Cr  ALP (U/L) 
OC 
(mmol/L) 
Control - 0.24 ± 0.02* 3.3 ± 0.3* 107.5±12.5* 7.6 ± 0.3* 
OVX - 0.48 ± 0.03 5.8 ± 0.4 231.2 ±26.8 15.1 ± 0.5 
E2 0.025 0.28 ± 0.02* 4.3 ± 0.2* 138.4±18.7* 9.6 ± 0.4* 
L-EBME+ 60 0.33±0.0.02* 5.5 ± 0.4 176.2±16.5* 11.3 ± 0.3 
M-EBME 120 0.37 ± 0.01* 4.3 ± 0.3* 154.5±15.2* 10.7 ± 0.2* 
H-EBME 240 0.26±0.0.02* 4.5 ± 0.2* 143.3±16.5* 8.8 ± 0.3* 
*P < 0.05 and **p < 0.01 versus OVX group. + L / M / H-EBME: low / middle / high dose of  
EBME (n = 10 rats). 
 
Biochemical parameters of serum and urine 
specimens 
 
Data presented in Table 4 show the effects of 
EBME on the biochemical parameters of OVX 
rats. Compared to the control group, U-Ca/Cr, U-
P/Cr, and serum ALP, and OC levels were 
significantly (p < 0.05) increased in the OVX 
group. However, EBME significantly decreased 
the U-Ca/Cr and ALP levels (p < 0.05) in a dose-
dependent manner. Higher dosage of EBME 
(120 or 240 mg/kg/day) decreased the U-P/Cr 
and OC levels significantly (p < 0.05) relative to 
the non-OVX control. Again, E2 administration 
also reversed these changes significantly. The 
effect of E2 on these parameters is similar to that 




Bone re-modeling is an important physiological 
process that exerts changes and impacts on 
bone strength [1]. Any interruption in bone 
remodeling, caused by menopause for example, 
will disturb the balance between formation and 
resorption with attendant loss in bone mass [14]. 
Therefore, OVX rats were used as animal model 
for human osteoporosis in vivo experiments. It 
has been reported that statistically significant 
bone loss can be seen after 30 days of exposure 
to OVX inducing agents [15], so treatment was 
initiated 4 weeks after OVX. Consistent with 
other studies, one the findings in the present 
study is that OVX caused significantly higher 
body weights gain, which may be attributed to fat 
deposition caused by the lack of estrogen. It has 
been proposed previously that the differentiation 
of progenitor cells may greatly rely on estrogen 
via the osteoblast lineage but not the adipocyte 
lineage [16]. 
 
Decreased BMD is believed to exert harmful 
impact on bone strength, leading to increased 
susceptibility to fractures [17]. Thus, 
measurement of BMD is can provide information 
for evaluating bone fracture risk [18,19]. The 
results in the present study showed that OVX 
reduced BMD in the right femurs and 4th lumber 
vertebrae, which are rich in trabecular bone. Also 
found was that EBME hindered the reduction of 
BMD in a dose-dependent manner. Although 
BMD is among the strongest predictors of bone 
susceptibility to facture, both empirical 
observations and theoretical analyses indicate 
that the biomechanical properties of bone and 
trabecular microarchitecture also affect 
trabecular bone strength [20]. Three-point 
bending tests of the left femurs in our study 
indicated that the higher extract doses (80 or 160 
mg/kg/day) prevented the OVX-induced 
tendency toward decreased biomechanical 
parameters. 
 
Measurements of structural parameters using 
micro-CT also showed that treatment with EBME 
effectively restored the trabecular micro-
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architectural properties compared to the OVX 
group. In addition, measurement of bone 
markers is an important approach to 
osteoporosis diagnosis and treatment [21]. Bone 
mass loss, as evidenced by enhanced levels of 
ALP, OC, U-Ca/Cr, and U-P/Cr, was an 
indication of the capacity of OVX to increase 
bone turnover. The alterations in values of bone 
turnover markers analyzed in this study were 
dose-dependently reversed by EBME. Evidently, 
the results presented here suggest that EBME is 
likely to be an effective agent for the treatment of 




The findings of this study show that EBME 
mitigates OVX-induced osteoporosis in rats. 
Therefore, the plant extract requires further 
investigation for possible management of 
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